Protalix Biotherapeutics Inc (PLX)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Dror Bashan
Employees:
200
2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL, ISRAEL 20100
972-4-988-9488

Protalix BioTherapeutics, Inc. focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials.

Data derived from most recent annual or quarterly report
Market Cap 115.28 Million Shares Outstanding57.353 Million Avg 30-day Volume 3.555 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.31
Price to Revenue2.934 Debt to Equity32.1617 EBITDA-13.646 Million
Price to Book Value119.75 Operating Margin-33.0643 Enterprise Value120.091 Million
Current Ratio1.758 EPS Growth0.415 Quick Ratio1.09
1 Yr BETA 0.2921 52-week High/Low 3.55 / 1.0 Profit Margin-38.3365
Operating Cash Flow Growth-253.0096 Altman Z-Score1.4076 Free Cash Flow to Firm -2.132 Million

Are you looking for this stock instead?

View SEC Filings from PLX instead.

View recent insider trading info

Protalix Biotherapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding PLX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PLX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-01-05 by SCHWARTZ AHARON
  • 4: filed on 2022-09-09 by BEN ZVI SHMUEL
  • 4: filed on 2022-09-09 by NAOS YARON
  • 4: filed on 2022-09-09 by HAYON YAEL
  • 4: filed on 2022-09-09 by RUBIN EYAL
  • 4: filed on 2022-09-09 by BASHAN DROR
  • 4: filed on 2022-09-09 by SCHWARTZ AHARON
  • 4: filed on 2022-09-09 by BRONFELD ZEEV
  • 4: filed on 2022-09-09 by BAR-SHALEV AMOS
  • 4: filed on 2022-09-09 by MELINCOFF GWEN A

    • Events (8k)

  • 8-K: filed on 2023-05-30:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-18:
    Item 2.02: Results of Operations and Financial Condition
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-10:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-05:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-27:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-27:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-24:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-03:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-27:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    SCHWARTZ AHARON

    • Director
    		 174,000 2023-01-03 2

    BRONFELD ZEEV

    • Director
    		 100,000 2022-09-07 1

    BAR-SHALEV AMOS

    • Director
    		 50,000 2022-09-07 1

    BOUDES POL F

    • Director
    		 50,000 2022-09-07 1

    MELINCOFF GWEN A

    • Director
    		 50,000 2022-09-07 1

    RUBIN EYAL SR. VP AND CFO

    • Officer
    		 350,000 2022-09-07 1

    NAOS YARON SR. VP, OPERATIONS

    • Officer
    		 340,000 2022-09-07 1

    BASHAN DROR PRESIDENT AND CEO

    • Officer
    • Director
    		 750,000 2022-09-07 1

    HAYON YAEL VP, RESEARCH & DEVELOPMENT

    • Officer
    		 250,000 2022-09-07 1

    BEN ZVI SHMUEL

    • Director
    		 10,000 2022-09-07 3

    DEXCEL PHARMA TECHNOLOGIES LTD.

    OREN DAN

    • 10% Owner
    		 No longer subject to file 2021-06-02 0

    ALMON EINAT BRILL SVP, CHIEF DEVELOPMENT OFFICER

    • Officer
    		 0 2020-06-07 0

    GRANOT DAVID

    • Director
    		 0 2020-01-20 0

    MAIMON YOSSI VP, CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2018-09-13 0

    SHAALTIEL YOSEPH EXECUTIVE VP, R&D

    • Officer
    		 0 2018-09-13 0

    MANOR MOSHE PRESIDENT & CEO

    • Officer
    • Director
    		 0 2018-09-13 0

    CAMBER CAPITAL MANAGEMENT LLC

    • 10% Owner
    		 No longer subject to file 2016-12-02 0

    PALASH TZVI CHIEF OPERATING OFFICER

    • Officer
    		 0 2015-03-23 0

    BIO-CELL LTD

    • 10% Owner
    		 No longer subject to file 2014-09-16 0

    YANAI SHLOMO

    • Director
    		 0 2014-07-24 0

    AKIROV ALFRED

    • Director
    		 4,915,383 2013-08-14 0

    AVIEZER DAVID PRESIDENT & CEO

    • Officer
    • Director
    		 418,000 2012-07-16 0

    LAUTERBACH SANDRA LEIGH VP, SALES & COMMERCIAL AFFAIRS

    • Officer
    		 20,000 2012-07-16 0

    HURVITZ ELI

    • Director
    		 5,353,923 2009-11-12 0

    FROST PHILLIP MD ET AL

    FROST GAMMA INVESTMENTS TRUST

    • 10% Owner
    		 7,610,167 2009-09-09 0

    KORNBERG ROGER D.

    • Director
    		 0 2008-02-07 0

    GROSS YODFAT HAREL

    • Director
    		 0 2007-06-26 0

    KATZ IFTAH VP OF OPERATIONS

    • Officer
    		 204,351 2007-05-15 0

    HSIAO JANE PH D

    • Director
    		 1,134,060 2007-01-31 0

    FROST PHILLIP MD ET AL

    • Director
    • 10% Owner
    		 11,754,213 2006-12-31 0

    LOCKSHIN CURTIS

    • Director
    		 0 2006-07-05 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    PROTALIX BIOTHERAPEUTICS INC PLX 2023-05-31 22:15:04 UTC -33.8972 38.9572 650000
    PROTALIX BIOTHERAPEUTICS INC PLX 2023-05-31 21:45:04 UTC -33.8972 38.9572 650000
    PROTALIX BIOTHERAPEUTICS INC PLX 2023-05-31 21:15:03 UTC -33.8972 38.9572 650000
    PROTALIX BIOTHERAPEUTICS INC PLX 2023-05-31 20:45:04 UTC -33.8972 38.9572 650000
    PROTALIX BIOTHERAPEUTICS INC PLX 2023-05-31 20:15:06 UTC -34.1307 39.1907 650000
    PROTALIX BIOTHERAPEUTICS INC PLX 2023-05-31 19:45:04 UTC -34.1307 39.1907 650000
    PROTALIX BIOTHERAPEUTICS INC PLX 2023-05-31 19:15:21 UTC -34.2547 39.3147 650000
    PROTALIX BIOTHERAPEUTICS INC PLX 2023-05-31 18:45:03 UTC -34.2547 39.3147 650000
    PROTALIX BIOTHERAPEUTICS INC PLX 2023-05-31 18:15:04 UTC -34.2547 39.3147 650000
    PROTALIX BIOTHERAPEUTICS INC PLX 2023-05-31 17:45:03 UTC -34.2547 39.3147 650000
    PROTALIX BIOTHERAPEUTICS INC PLX 2023-05-31 17:15:05 UTC -34.2547 39.3147 650000
    PROTALIX BIOTHERAPEUTICS INC PLX 2023-05-31 16:45:04 UTC -34.5401 39.6101 650000
    PROTALIX BIOTHERAPEUTICS INC PLX 2023-05-31 16:15:04 UTC -34.5401 39.6101 550000
    PROTALIX BIOTHERAPEUTICS INC PLX 2023-05-31 15:45:03 UTC -34.5401 39.6101 550000
    PROTALIX BIOTHERAPEUTICS INC PLX 2023-05-31 15:15:04 UTC -34.5401 39.6101 550000
    PROTALIX BIOTHERAPEUTICS INC PLX 2023-05-31 14:45:04 UTC -34.5401 39.6101 550000
    PROTALIX BIOTHERAPEUTICS INC PLX 2023-05-31 14:15:03 UTC -34.5401 39.6101 550000
    PROTALIX BIOTHERAPEUTICS INC PLX 2023-05-31 13:45:04 UTC -27.9893 33.0593 250000
    PROTALIX BIOTHERAPEUTICS INC PLX 2023-05-31 13:15:04 UTC -27.9893 33.0593 250000
    PROTALIX BIOTHERAPEUTICS INC PLX 2023-05-31 12:45:04 UTC -27.9893 33.0593 250000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments